March 6, 2018 09:51 AM EST
Financing

View­Point Ther­a­peu­tics gets $35M to ad­vance non-sur­gi­cal al­ter­na­tive for cataracts, pres­by­opia

Amber Tong

With help from a so­cial­ly con­scious fund, San Fran­cis­co pro­tein mis­fold­ing up­start View­Point Ther­a­peu­tics has raised $35 mil­lion to take its eye drugs through proof …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times